drugset / Trial / NCT05002127
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Timeline
- Start
- 2022-01-15
- Primary completion
- 2024-05-24
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evorpacept | Protein / enzyme biologic | 30 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Background | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |